How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

  • Question on Consultation

    There is a requirement for relevant health bodies to comply with the recommendations in this evaluation within 3 months of the date final guidance is published by NICE (see section 4.1). We are aware there may be system challenges that mean an extension to this normal period may be appropriate because tirzepatide cannot be appropriately administered until:
    • training is in place
    • certain health service infrastructure requirements including goods, materials or other facilities are in place
    • other appropriate health services resources, including staff, are in place. These challenges may include:
    • commissioning arrangements for weight management services
    • how tirzepatide will fit into the current treatment pathway for weight management
    • the provision of counselling, psychological support and concomitant behavioural, dietary and physical activity advice
    • titration of tirzepatide and how a stopping rule based on treatment response at 6 months would be implemented
    • capacity in the system.

  • Question on Consultation

    Please specify any potential challenges with implementing these recommendations and the associated reasons.

  • Question on Consultation

    Please also provide any ways to overcome these potential challenges, any estimate of the time period within which the recommendation can be complied with, and any approaches to phase in funding to manage access to tirzepatide during any potential extended funding variation period.
The content on this page is not current guidance and is only for the purposes of the consultation process.

Tirzepatide for managing overweight and obesity

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about tirzepatide

Marketing authorisation indication

2.1

Tirzepatide (Mounjaro, Eli Lilly) is indicated 'for weight management, including weight loss and weight maintenance as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of

  • ≥30 kg/m2 (obesity) or

  • ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus)'.

Price

2.3

The list prices of tirzepatide (4-week supply of pre-filled pen devices for subcutaneous injection) are:

  • £92.00 for 2.5 mg and 5 mg

  • £107.00 for 7.5 mg and 10 mg

  • £122.00 for 12.5 mg and 15 mg